Efficacy and safety of colchicine treatment in patients with COVID‐19 : A prospective, multicenter, randomized clinical trial
Abstract Colchicine has shown clinical benefits in the management of COVID‐19 via its anti‐inflammatory effect. However, the exact role of colchicine in COVID‐19 patients is unknown. The current clinical trial was performed on 202 patients with moderate to severe COVID‐19. Patients were randomly assigned in a 1:1 ratio to receive up to a 3‐day course of 0.5 mg colchicine followed by a 12‐day course of 1 mg colchicine in combination with standard care or a 15‐day course of standard care. Among 202 randomized patients, 153 completed the study and received colchicine/standard care or continued standard care ( M age, 54.72 [ SD, 15.03] years; 93 [63.1%] men). On day 14, patients in the colchicine/standard care group had significantly higher odds of a better clinical status distribution on chest CT evaluation ( p = .048). Based on NYHA classification, the percentage change of dyspnea on day 14 between groups was statistically significant ( p = .026), indicating a mean of 31.94% change in the intervention group when compared with 19.95% in the control group. According to this study, colchicine can improve clinical outcomes and reduce pulmonary infiltration in COVID‐19 patients if contraindications and precautions are considered and it is prescribed at the right time and in appropriate cases..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Phytotherapy Research - 36(2022), 2, Seite 891-898 |
| Beteiligte Personen: |
Pourdowlat, Guitti [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© 2022 John Wiley & Sons, Ltd. |
|---|
| Umfang: |
8 |
|---|
| doi: |
10.1002/ptr.7319 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY012681415 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY012681415 | ||
| 003 | DE-627 | ||
| 005 | 20230308010406.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230220s2022 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1002/ptr.7319 |2 doi | |
| 028 | 5 | 2 | |a PTR_PTR7319.xml |
| 035 | |a (DE-627)WLY012681415 | ||
| 035 | |a (WILEY)PTR7319 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.98 |2 bkl | ||
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a Pourdowlat, Guitti |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy and safety of colchicine treatment in patients with COVID‐19 |b A prospective, multicenter, randomized clinical trial |
| 264 | 1 | |c 2022 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2022 John Wiley & Sons, Ltd. | ||
| 520 | |a Abstract Colchicine has shown clinical benefits in the management of COVID‐19 via its anti‐inflammatory effect. However, the exact role of colchicine in COVID‐19 patients is unknown. The current clinical trial was performed on 202 patients with moderate to severe COVID‐19. Patients were randomly assigned in a 1:1 ratio to receive up to a 3‐day course of 0.5 mg colchicine followed by a 12‐day course of 1 mg colchicine in combination with standard care or a 15‐day course of standard care. Among 202 randomized patients, 153 completed the study and received colchicine/standard care or continued standard care ( M age, 54.72 [ SD, 15.03] years; 93 [63.1%] men). On day 14, patients in the colchicine/standard care group had significantly higher odds of a better clinical status distribution on chest CT evaluation ( p = .048). Based on NYHA classification, the percentage change of dyspnea on day 14 between groups was statistically significant ( p = .026), indicating a mean of 31.94% change in the intervention group when compared with 19.95% in the control group. According to this study, colchicine can improve clinical outcomes and reduce pulmonary infiltration in COVID‐19 patients if contraindications and precautions are considered and it is prescribed at the right time and in appropriate cases. | ||
| 700 | 1 | |a Saghafi, Fatemeh |4 aut | |
| 700 | 1 | |a Mozafari, Abolfazl |4 aut | |
| 700 | 1 | |a Sahebnasagh, Adeleh |4 aut | |
| 700 | 1 | |a Abedini, Atefeh |4 aut | |
| 700 | 1 | |a Nabi Meybodi, Mohsen |4 aut | |
| 700 | 1 | |a Salehi Nezamabadi, Ali |4 aut | |
| 700 | 1 | |a Mousavinasab, Seyed Ruhollah |4 aut | |
| 700 | 1 | |a Kiani, Arda |4 aut | |
| 700 | 1 | |a Raji, Hanieh |4 aut | |
| 700 | 1 | |a Soltani, Nadia |4 aut | |
| 700 | 1 | |a Gholmzadeh Baeis, Mehdi |4 aut | |
| 700 | 1 | |a Eidani, Esmaeil |4 aut | |
| 700 | 1 | |a Sadeghi Yakhdani, Abdolrahim |4 aut | |
| 700 | 1 | |a Movaseghi, Fatemeh |4 aut | |
| 700 | 1 | |a Habtemariam, Solomon |4 aut | |
| 700 | 1 | |a Akhoundi Meybodi, Zohreh |4 aut | |
| 700 | 1 | |a Gholinataj Jelodar, Mohsen |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Phytotherapy Research |g 36(2022), 2, Seite 891-898 |w (DE-627)WLY012671339 |x 10991573 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2022 |g number:2 |g pages:891-898 |g extent:8 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-ASE | ||
| 936 | b | k | |a 44.98 |q ASE |
| 936 | b | k | |a 44.40 |q ASE |
| 951 | |a AR | ||
| 952 | |d 36 |j 2022 |e 2 |h 891-898 |g 8 | ||